Breaking News Instant updates and real-time market news.

SHAK

Shake Shack

$83.66

0.905 (1.09%)

, UBER

Uber

$30.99

-0.33 (-1.05%)

14:02
11/04/19
11/04
14:02
11/04/19
14:02

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Uber (UBER), consensus (81c)... Shake Shack (SHAK), consensus 20c... nLIGHT(LASR), consensus 2c... Aaron's (AAN), consensus 82c... Myriad Genetics (MYGN), consensus 32c.

SHAK

Shake Shack

$83.66

0.905 (1.09%)

UBER

Uber

$30.99

-0.33 (-1.05%)

LASR

nLight

$14.69

0.58 (4.11%)

AAN

Aaron's

$73.01

-0.98 (-1.32%)

MYGN

Myriad Genetics

$34.83

1.03 (3.05%)

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

SHAK Shake Shack
$83.66

0.905 (1.09%)

10/25/19
WEDB
10/25/19
NO CHANGE
Target $84
WEDB
Neutral
Wedbush favors Dine Brands, 'cautious' on Cheesecake Factory into Q3 earnings
Wedbush analyst Nick Setyan told investors in a research note that he favors Applebee's parent Dine Brands (DIN) and is "cautious" on Cheesecake Factory (CAKE) ahead of Q3 their earnings reports. The analyst raised his price target for Shake Shack (SHAK) to $84 from $75, but lowered his price targets for Dunkin' Brands (DNKN) to $90 from $92, for Cheesecake Factory to $40 from $43, for Starbucks (SBUX) to $86 from $95, for Texas Roadhouse (TXRH) to $52 from $60 and for Wingstop (WING) to $88 from $92.
09/30/19
09/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with a Hold at Deutsche Bank. 2. Bellus Health (BLU) initiated with a Buy at Jefferies as well as Guggenheim, and an Outperform at Cowen. 3. Idex Corp. (IEX) initiated with a Neutral at Citi. 4. Global Ship Lease (GSL) initiated with a Buy at B. Riley FBR. 5. Murphy Oil (MUR) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
DBAB
09/30/19
INITIATION
Target $90
DBAB
Hold
Deutsche Bank starts Shake Shack at Hold, says wait for better entry point
Deutsche Bank analyst Brian Mullan initiated coverage of Shake Shack with a Hold rating and $90 price target. The stock closed Friday down $2.01 to $95.52. Shake Shack is a "truly differentiated brand" within the restaurant industry and has a "compelling" long-term growth opportunity, Mullan tells investors in a research note. However, with the shares up 115% year-to-date, the analyst thinks the market is pricing in a lot of the positive factors at this point in time. As such, he advocates patience and prefers to wait for a better entry point into Shake Shack shares.
09/30/19
DBAB
09/30/19
INITIATION
Target $90
DBAB
Hold
Shake Shack initiated with a Hold at Deutsche Bank
Deutsche Bank started Shake Shack with a Hold rating and $90 price target.
UBER Uber
$30.99

-0.33 (-1.05%)

10/31/19
GSCO
10/31/19
UPGRADE
Target $58
GSCO
Buy
Lyft upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Lyft (LYFT) to Buy from Neutral with a price target of $58, down from $71. The stock in premarket trading is up 4%, or $1.92, to $46.03. The company reported better than expected Q3 revenue and management noted a trend toward higher prices across the industry, incremental engagement per rider, and a less promotional competitive environment, Terry tells investors in a research note. Lyft continues to gain share and is beginning to show the operational efficiencies, says the analyst, who believes the stock's risk/reward is favorable at current levels. Lyft competitor Uber Technologies (UBER) is trading up 15c to $33.90.
10/28/19
DBAB
10/28/19
NO CHANGE
Target $29
DBAB
Hold
Uber launch could drive adoption of Green Dot powered card, says Deutsche Bank
Deutsche Bank analyst Ashish Sabadra said the launch of Uber Money (UBER) could drive greater adoption of the Uber debit card, which is powered by Green Dot (GDOT). Since there are no monthly fees for the debit card account, Sabadra thinks the primary monetization will be through interchange and other fees. The analyst keeps a Hold rating on Green Dot shares with a $29 price target.
10/25/19
NRCS
10/25/19
NO CHANGE
NRCS
Neutral
Northcoast checks show 'healthy' ride-hailing conditions during Q3
Northcoast analyst John Healy says his Q3 channel checks into ride-hailing conditions in the U.S. market indicate a backdrop that was "healthy at the margin with no meaningful slowdown." Further, Uber Technologies (UBER) seemed to win some of the "tug-of-war battle" between itself and Lyft (LYFT), as drivers seemed "marginally more pleased" with their time spent with Uber, Healy tells investors in a research note. He believes that at the margin, drivers during Q3 moved a bit more of their usage towards Uber. Meanwhile, Lyft continues to "inch pricing higher" for rides in many markets, while Uber is taking a more wait and see approach, says Healy. The analyst raised his Q3 earnings per share estimate for Lyft to (61c) from (72c), and lowered his Q3 estimate for Uber to (65c) from (63c). Healy keeps a Neutral rating on both stocks, but sees Lyft as the "cleaner/pure play story and at the margin more attractive."
10/25/19
10/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Essa Pharma (EPIX) initiated with an Outperform at Oppenheimer. 2. Uber (UBER) initiated with a Buy at Guggenheim. 3. LogMeln (LOGM) assumed with a Sector Perform at RBC Capital. 4. MannKind (MNKD) initiated with an Overweight at Cantor Fitzgerald. 5. Sanderson Farms (SAFM) initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
LASR nLight
$14.69

0.58 (4.11%)

08/06/19
ADAM
08/06/19
NO CHANGE
Target $18
ADAM
Buy
nLight price target lowered to $18 from $28 at Canaccord
Canaccord analyst Jed Dorsheimer lowered his price target on nLight to $18 from $28 following its inline Q2 results and lowered guidance. The guidance was not shocking given the recent commentary surrounding China that other industry participants have reported. In addition to China weakness, price competition is intense in lower power lasers so investors should focus on the longer-term opportunity for the company. Dorsheimer maintained his Buy rating on nLight shares.
08/06/19
CHLM
08/06/19
NO CHANGE
Target $16
CHLM
Hold
nLight price target lowered to $16 from $23 at Craig-Hallum
Craig-Hallum analyst Greg Palm lowered his price target for nLight to $16 from $23 after the company reported mixed results. While Q2 was essentially in-line, Q3 guidance and the implied outlook for Q4 was considerably worse, he notes. The analyst reiterates a Hold rating on the shares.
08/06/19
DADA
08/06/19
NO CHANGE
Target $20
DADA
nLight price target lowered to $20 from $28 at DA Davidson
DA Davidson analyst Thomas Diffely lowered his price target on nLight to $20 after its Q2 earnings miss and below-consensus Q3 revenue guidance, saying its quarters echoed the industry concerns around the escalating trade tensions between U.S. and China. The analyst also cites the slowing industrial laser market and the pricing pressure coming from the company's domestic competitors in China, stating that there is now "little visibility into the timing or magnitude of a recovery." Diffely maintains a Buy rating on nLight longer term, adding that the company's Aerospace and Defense segment remains a "bright spot" with its sixth consecutive quarter of double-digit growth.
07/17/19
NEED
07/17/19
NO CHANGE
Target $21
NEED
Buy
nLight price target lowered to $21 from $26 at Needham
Needham analyst James Ricchiuti lowered his price target on nLight to $21 to reflect the slowing conditions in the Industrial and Microfabrication areas of its business. The analyst keeps his Buy rating on the stock however and believes that the company can navigate the "choppy macro environment", stating that its microfabrication business is "diverse enough" to insulate it from cyclically weak markets. Ricchiuti adds that nLight's underperformance relative to its peer group is unwarranted.
AAN Aaron's
$73.01

-0.98 (-1.32%)

10/16/19
RAJA
10/16/19
NO CHANGE
Target $80
RAJA
Strong Buy
Aaron's price target raised to $80 from $72 at Raymond James
Raymond James analyst Budd Bugatch raised his price target for Aaron's (AAN) to $80 from $72 and reiterated a Strong Buy rating following the recent news that Lowe's (LOW) had rolled out the Aaron's/Progressive virtual lease-to-own program nationwide. Bugatch tells investors in a research note that he believes this will be a terrific "win" for Progressive and create much value for Aaron's and says he can envision ~$30 in permanent incremental share value.
09/26/19
BOFA
09/26/19
INITIATION
Target $75
BOFA
Buy
Aaron's initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Haas initiated Aaron's (AAN) with a Buy rating and a price target of $75. The analyst expects the company to produce "significant upside" to revenue and EPS from the large national retailer partnerships in its Progressive Leasing segment, adding that its rent-to-own contracts through Best Buy (BBY), Lowe's (LOW), Wayfair (W) and Overstock (OSTK) could more than double the company's sales and earnings over time.
09/26/19
09/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dropbox (DBX) assumed with an Outperform at RBC Capital. 2. Rigel Pharmaceuticals (RIGL) assumed with an Overweight at JPMorgan. 3. Aaron's (AAN) initiated with a Buy at BofA/Merrill. 4. Cooper-Standard (CPS) resumed with a Buy at Roth Capital. 5. Carvana (CVNA) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/19
LOOP
10/21/19
NO CHANGE
Target $90
LOOP
Buy
Aaron's price target raised to $90 from $73 at Loop Capital
Loop Capital analyst Anthony Chukumba raised his price target on Aaron's (AAN) to $90 and kept his Buy rating ahead of its Q3 results on November 4th, reflecting the company's recent announcement of rolled out Progressive offering at Lowe's (LOW) nationwide. The analyst expects investors to focus on the management's earnings call commentary regarding Progressive sales and the "invoice volume per active door" growth metric, along with any updates on its partnership with Best Buy (BBY). Chukumba is also raising his FY20 EPS view on Aaron's to $4.97 from $4.54.
MYGN Myriad Genetics
$34.83

1.03 (3.05%)

09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker (BRKR), PerkinElmer (PKI), and Personalis (PSNL) to Buy from Neutral as part of his broader research note into Life Sciences & Diagnostic Tools. The analyst notes that the recent market volatility has sent many of the names in the sector "sharply lower", making their valuations more attractive. de Bruin is also positive on Bruker's new product portfolio and margin expansion opportunity. As part of the research note, the analyst cuts Myriad Genetics (MYGN) to Underperform from Neutral and lowers his price target on the shares to $28 from $30 after a bounce in its stock price and given his concern with its mixed execution.
09/26/19
BOFA
09/26/19
DOWNGRADE
BOFA
Underperform
Myriad Genetics downgraded to Underperform from Neutral at BofA/Merrill
09/25/19
LEHM
09/25/19
NO CHANGE
Target $22
LEHM
Underweight
Barclays, following 'regulatory breadcrumbs,' stays Underweight on Myriad
The most important debate for shares of Myriad Genetics remains potential regulatory action for GeneSight, Barclays analyst Jack Meehan tells investors in a research note. The analyst believes recent "regulatory breadcrumbs" confirm the risks inherent in his Underweight thesis on Myriad shares. The most recent important update was a letter submitted by the American Clinical Laboratory Association to the FDA on September 18 saying that the ACLA is "Deeply Concerned by FDA Actions on Pharmacogenetic Testing," says Meehan. If the lab industry were having positive FDA dialogue, there would have been no need to publish a formal four-page letter raising concerns about the regulatory review taking place, contends the analyst. He believes potential premarket approval application review of the test would raise further regulatory risk for GeneSight.
09/24/19
PIPR
09/24/19
NO CHANGE
Target $40
PIPR
Neutral
Myriad competitor allowed to keep pharmacogenomic stoplight, says Piper Jaffray
Myriad Genetics competitor Genomind resumed including specific drug recommendations in physician reports following interaction with FDA, but only for physician clients as patient reports only include the genotype information, Piper Jaffray analyst William Quirk tells investors in a research note. While there remains considerable uncertainty in the pharmacogenomics landscape, the recent move by Genomind is a positive read through for Myriad's GeneSight, says the analyst. He points out that several industry groups are lobbying the FDA to reverse their recent action against pharmacogenomic Clinical Laboratory Improvement Amendments-certified labs. This suggests the GeneSight psychotropic test report could remain on market as is, contends Quirk. He keeps a Neutral rating on shares of Myriad Genetics.

TODAY'S FREE FLY STORIES

CDE

Coeur Mining

$5.86

-1.17 (-16.64%)

05:41
01/21/20
01/21
05:41
01/21/20
05:41
Downgrade
Coeur Mining rating change  »

Coeur Mining downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LGF.B

Lionsgate

$10.32

-0.305 (-2.87%)

05:39
01/21/20
01/21
05:39
01/21/20
05:39
Downgrade
Lionsgate rating change  »

Lionsgate downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

USB

U.S. Bancorp

$55.33

0.14 (0.25%)

05:36
01/21/20
01/21
05:36
01/21/20
05:36
Downgrade
U.S. Bancorp rating change  »

U.S. Bancorp downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 15

    Apr

CHGG

Chegg

$43.36

0.64 (1.50%)

05:34
01/21/20
01/21
05:34
01/21/20
05:34
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 19

    Feb

ROKU

Roku

$130.35

-0.76 (-0.58%)

05:33
01/21/20
01/21
05:33
01/21/20
05:33
Hot Stocks
Roku announces arrival in Brazil through partnership with AOC »

Roku announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

RNR

RenaissanceRe

$193.19

0.235 (0.12%)

05:32
01/21/20
01/21
05:32
01/21/20
05:32
Initiation
RenaissanceRe initiated  »

RenaissanceRe initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

RE

Everest Re

$279.96

2.455 (0.88%)

05:31
01/21/20
01/21
05:31
01/21/20
05:31
Initiation
Everest Re initiated  »

Everest Re initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

COST

Costco

$304.68

1.83 (0.60%)

05:31
01/21/20
01/21
05:31
01/21/20
05:31
Upgrade
Costco rating change  »

Costco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Mar

HIG

Hartford Financial

$61.20

0.925 (1.53%)

05:30
01/21/20
01/21
05:30
01/21/20
05:30
Initiation
Hartford Financial initiated  »

Hartford Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

UBS

UBS

$13.13

-0.06 (-0.45%)

05:29
01/21/20
01/21
05:29
01/21/20
05:29
Hot Stocks
UBS agrees to sell majority stake in UBS Fondcenter to Clearstream »

UBS Group AG and UBS AG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

AIG

AIG

$52.88

0.52 (0.99%)

05:29
01/21/20
01/21
05:29
01/21/20
05:29
Initiation
AIG initiated  »

AIG initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$140.72

1.85 (1.33%)

05:28
01/21/20
01/21
05:28
01/21/20
05:28
Initiation
Travelers initiated  »

Travelers initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CB

Chubb

$153.67

1 (0.66%)

05:28
01/21/20
01/21
05:28
01/21/20
05:28
Initiation
Chubb initiated  »

Chubb initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

PGR

Progressive

$76.29

0.85 (1.13%)

05:27
01/21/20
01/21
05:27
01/21/20
05:27
Initiation
Progressive initiated  »

Progressive initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALL

Allstate

$117.54

1.39 (1.20%)

05:26
01/21/20
01/21
05:26
01/21/20
05:26
Initiation
Allstate initiated  »

Allstate initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

  • 13

    Mar

UBS

UBS

$13.13

-0.06 (-0.45%)

05:26
01/21/20
01/21
05:26
01/21/20
05:26
Hot Stocks
UBS targeting RoCET1 of 12%-15% om 2020-2022 »

UBS provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

WLTW

Willis Towers Watson

$204.95

0.76 (0.37%)

05:25
01/21/20
01/21
05:25
01/21/20
05:25
Initiation
Willis Towers Watson initiated  »

Willis Towers Watson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 28

    Jan

  • 06

    Feb

  • 10

    Feb

  • 11

    Feb

  • 11

    Feb

MMC

Marsh & McLennan

$114.11

1.32 (1.17%)

05:24
01/21/20
01/21
05:24
01/21/20
05:24
Initiation
Marsh & McLennan initiated  »

Marsh & McLennan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

AON

Aon plc

$211.77

1.66 (0.79%)

05:24
01/21/20
01/21
05:24
01/21/20
05:24
Initiation
Aon plc initiated  »

Aon plc initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 26

    Feb

UBS

UBS

$13.13

-0.06 (-0.45%)

05:24
01/21/20
01/21
05:24
01/21/20
05:24
Earnings
UBS reports Q4 EPS 19c, one estimate 18c »

Reports Q4 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

PING

Ping Identity

$25.68

-0.34 (-1.31%)

05:19
01/21/20
01/21
05:19
01/21/20
05:19
Downgrade
Ping Identity rating change  »

Ping Identity downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNG

RingCentral

$192.99

2.36 (1.24%)

, AVYA

Avaya

$12.97

(0.00%)

05:17
01/21/20
01/21
05:17
01/21/20
05:17
Upgrade
RingCentral, Avaya rating change  »

RingCentral upgraded to…

RNG

RingCentral

$192.99

2.36 (1.24%)

AVYA

Avaya

$12.97

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$46.57

-0.37 (-0.79%)

05:15
01/21/20
01/21
05:15
01/21/20
05:15
Earnings
Logitech backs FY20 revenue guidance of mid to high single-digit growth »

Backs FY20 non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

GLNCY

Glencore

$0.00

(0.00%)

05:14
01/21/20
01/21
05:14
01/21/20
05:14
Upgrade
Glencore rating change  »

Glencore upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$46.57

-0.37 (-0.79%)

05:14
01/21/20
01/21
05:14
01/21/20
05:14
Earnings
Logitech reports Q3 EPS 84c, consensus 79c »

Reports Q3 revenue $903M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.